Biogen's Spinraza yields long-term preservation of motor development in SMA

Gearing up to compete with a gene therapy in SMA, Biogen presented long-term data from its antisense therapy Spinraza that could help make the case for continued use of the chronic treatment.

In the open-label Phase II NURTURE trial, Biogen Inc. (NASDAQ:BIIB) found that after treatment with Spinraza nusinersen for up to 45 months, all 25 spinal muscular atrophy patients were able to sit without support, while 88% could walk independently and had achieved motor milestones within a "normal timeframe." ...